CoChat

Effects of MetAP2 inhibition on hyperphagia and body weight in Prader–Willi syndrome: A randomized, double‐blind, placebo‐controlled trial

Open access
McCandless, Shawn E., Yanovski, Jack A., Miller, Jennifer, Fu, Cary, Bird, Lynne M., Salehi, Parisa, Chan, Christine L., Stafford, Diane, Abuzzahab, M. Jennifer, Viskochil, David, Barlow, Sarah E., Angulo, Moris, Myers, Susan E., Whitman, Barbara Y., Styne, Dennis, Roof, Elizabeth, Dykens, Elisabeth M., Scheimann, Ann O., Malloy, Jaret, Zhuang, Dongliang, Taylor, Kristin, Hughes, Thomas E., Kim, Dennis D., Butler, Merlin G. · 2017 · Diabetes, Obesity and Metabolism
Cited by 108

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims: There are no treatments for the extreme hyperphagia and obesity in Prader–Willi syndrome ( PWS ). The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 ( MetAP 2) inhibitor, beloranib. Materials and Methods: Participants with PWS (12‐65 years old) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Co‐primary endpoints were the changes in hyperphagia [measured by Hyperphagia Questionnaire for Clinical Trials ( HQ ‐ CT ); possible score 0‐36] and weight by intention‐to‐treat. ClinicalTrials.gov registration: NCT02179151 . Results: One‐hundred and seven participants were included in the intention‐to‐treat analysis: placebo ( n = 34); 1.8 mg beloranib ( n = 36); or 2.4 mg beloranib ( n = 37). Improvement (reduction) in HQ‐CT total score was greater in the 1.8 mg (mean difference −6.3, 95% CI −9.6 to −3.0; P = .0003) and 2.4 mg beloranib groups (−7.0, 95% CI −10.5 to −3.6; P = .0001) vs placebo. Compared with placebo, weight change was greater with 1.8 mg (mean difference − 8.2%, 95% CI −10.8 to −5.6; P < .0001) and 2.4 mg beloranib (−9.5%, 95% CI −12.1 to −6.8; P < .0001). Injection site bruising was the most frequent adverse event with beloranib. Dosing was stopped early due to an imbalance in venous thrombotic events in beloranib‐treated participants (2 fatal events of pulmonary embolism and 2 events of deep vein thrombosis) compared with placebo. Conclusions: MetAP2 inhibition with beloranib produced statistically significant and clinically meaningful improvements in hyperphagia‐related behaviours and weight loss in participants with PWS . Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13021

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 108

Metadata

Authors
McCandless, S. E., Yanovski, J. A., Miller, J., Fu, C., Bird, L. M., Salehi, P., Chan, C. L., Stafford, D., Abuzzahab, M. J., Viskochil, D., Barlow, S. E., Angulo, M., Myers, S. E., Whitman, B. Y., Styne, D., Roof, E., Dykens, E. M., Scheimann, A. O., Malloy, J., Zhuang, D., Taylor, K., Hughes, T. E., Kim, D. D., & Butler, M. G.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-07-13
Volume
19
Issue
12
Pages
1751-1761
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2618318751
Cited by
108
References
7
FWCI
7.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of MetAP2 inhibition on hyperphagia and body weight in Prader–Willi syndrome: A randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/dom.13021
The paper
McCandless, S. E., Yanovski, J. A., Miller, J., Fu, C., Bird, L. M., Salehi, P., Chan, C. L., Stafford, D., Abuzzahab, M. J., Viskochil, D., Barlow, S. E., Angulo, M., Myers, S. E., Whitman, B. Y., Styne, D., Roof, E., Dykens, E. M., Scheimann, A. O., Malloy, J., . . . Butler, M. G. (2017). Effects of MetAP2 inhibition on hyperphagia and body weight in Prader–Willi syndrome: A randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.